Advanced Accounting 12th Edition by Joe Ben Hoyle,Thomas Schaefer , Timothy Doupnik

Exercise 30

On March 7, 2012, Celgene Corporation acquired all of the outstanding stock of Avila Therapeutics, Inc. in exchange for $352.2 million in cash plus contingent consideration. Referring to Celgene's 2012 financial statements answer the following questions regarding the Avila Therapeutics acquisition.
What accounting method was used, and for what amount, to record the acquisition